Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers ...

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary - Cancer rates are rising everywhere ...

Delhi has long stood as a beacon of modern healthcare. The national capital is home to gleaming hospitals, internationally ...

Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicin ...

Some researchers suspect the trend has to do with obesity and diet. Others point to changes in the gut microbiome.

While gastroenterology deal activity has declined sharply over the past three years, momentum is expected to continue as independent practices pursue consolidation to gain scale and modernization ...

Hospitals are ramping up investment in gastroenterology to meet rising demand, expand outpatient services and boost revenue in a shifting care landscape. GI conditions cost the U.S. about $120 billion ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts ...

DelveInsight's Claudin 18.2 Directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report ...

A new paper in BJS, published by Oxford University Press, indicates that early-onset gastrointestinal cancer rates are rising dramatically across the globe.

Yiviva Presents Phase 2b Results for YIV-906 in Combination with Sorafenib in Advanced Hepatocellular Carcinoma at ASCO and ESMO GI 2025 ...